Background: Inhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are first-line treatments in patients with ALK-positive lung cancer. The FDA label warns of the risk of interstitial lung ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

As a consequence of these gene profiling studies ... in melanoma and the use of crizotinib (a MET inhibitor that blocks ALK) for the treatment of non-small cell lung carcinoma with ALK ...

The Alkaline Phosphatase pipeline drugs market research report outlays comprehensive information on the Alkaline Phosphatase targeted therapeutics, complete with analysis by indications, stage of ...

Sep. 25, 2024 — Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to the new results of an ...

The ALK Tyrosine Kinase Receptor pipeline drugs market research report outlays comprehensive information on the ALK Tyrosine Kinase Receptor targeted therapeutics, complete with analysis by ...

Mr. Yusheng Han, Founder and CEO of Burning Rock stated: "We are thrilled to have carried out a deep companion diagnostic collaboration with the global biopharmaceutical company Dizal. This ...

if their tumor has an abnormal “EGFR” or “ALK” gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study ACP1-High tumors ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...